To determine the associations of total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol with mortality from coronary heart disease and cardiovascular disease, we studied 2541 white men who were 40 to 69 years old at base line and followed them for an average of 10.1 years. Seventeen percent had some manifestation of cardiovascular disease at base line, whereas the others did not. Among the men who had cardiovascular disease at base line, we found, after multivariate adjustment, that those with "high" blood cholesterol levels (above 6.19 mmol per liter) had a risk of death from cardiovascular disease, including coronary heart disease, that was 3.45 times higher (95 percent confidence interval, 1.63 to 7.33) than that for men with "desirable" blood cholesterol levels (below 5.16 mmol per liter). The corresponding hazard ratios were 5.92 (95 percent confidence interval, 2.59 to 13.51) for LDL cholesterol levels above 4.13 mmol per liter as compared with those below 3.35 mmol per liter, and 6.02 (95 percent confidence interval, 2.73 to 13.28) for HDL cholesterol levels below 0.90 mmol per liter as compared with those above 1.16 mmol per liter. All three lipid levels were also significant predictors of death from coronary heart disease alone (P less than 0.005). Total cholesterol and LDL cholesterol levels were also significant predictors of death from cardiovascular and coronary heart disease in men without preexisting cardiovascular disease, although at a lower level of absolute risk of death. Thus, the 10-year risk of death from cardiovascular disease for a man with preexisting cardiovascular disease increased from 3.8 percent to almost 19.6 percent with increasing levels of total cholesterol from "desirable" to "high," whereas the corresponding risk for a man who was free of cardiovascular disease at base line increased from 1.7 percent to 4.9 percent. Our findings suggest that total, LDL, and HDL cholesterol levels predict subsequent mortality in men 40 to 69 years of age, especially those with preexisting cardiovascular disease.
Source Information
Department of Biostatistics, University of North Carolina, Chapel Hill.
This article has been cited by other articles:
Calkin, A. C., Drew, B. G., Ono, A., Duffy, S. J., Gordon, M. V., Schoenwaelder, S. M., Sviridov, D., Cooper, M. E., Kingwell, B. A., Jackson, S. P.
(2009). Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux. Circulation
120: 2095-2104
[Abstract][Full Text]
Patel, S., Drew, B. G., Nakhla, S., Duffy, S. J., Murphy, A. J., Barter, P. J., Rye, K.-A., Chin-Dusting, J., Hoang, A., Sviridov, D., Celermajer, D. S., Kingwell, B. A.
(2009). Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.. J Am Coll Cardiol
53: 962-971
[Abstract][Full Text]
Shaw, J. A., Bobik, A., Murphy, A., Kanellakis, P., Blombery, P., Mukhamedova, N., Woollard, K., Lyon, S., Sviridov, D., Dart, A. M.
(2008). Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque. Circ. Res.
103: 1084-1091
[Abstract][Full Text]
Xiao, C., Watanabe, T., Zhang, Y., Trigatti, B., Szeto, L., Connelly, P. W., Marcovina, S., Vaisar, T., Heinecke, J. W., Lewis, G. F.
(2008). Enhanced Cellular Uptake of Remnant High-Density Lipoprotein Particles: A Mechanism for High-Density Lipoprotein Lowering in Insulin Resistance and Hypertriglyceridemia. Circ. Res.
103: 159-166
[Abstract][Full Text]
O'Neil, C. E., Nicklas, T. A.
(2007). State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health. AMERICAN JOURNAL OF LIFESTYLE MEDICINE
1: 457-481
[Abstract]
Nogueira, J., Weir, M.
(2007). The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. CJASN
2: 766-785
[Abstract][Full Text]
Ito, M., Arishima, T., Kudo, T., Nishihara, E., Ohye, H., Kubota, S., Fukata, S., Amino, N., Kuma, K., Sasaki, I., Hiraiwa, T., Hanafusa, T., Takamatsu, J., Miyauchi, A.
(2007). Effect of Levo-Thyroxine Replacement on Non-High-Density Lipoprotein Cholesterol in Hypothyroid Patients. J. Clin. Endocrinol. Metab.
92: 608-611
[Abstract][Full Text]
Kovesdy, C. P., Anderson, J. E., Kalantar-Zadeh, K.
(2007). Inverse Association between Lipid Levels and Mortality in Men with Chronic Kidney Disease Who Are Not Yet on Dialysis: Effects of Case Mix and the Malnutrition-Inflammation-Cachexia Syndrome. J. Am. Soc. Nephrol.
18: 304-311
[Abstract][Full Text]
Leon, L. R. Jr, Labropoulos, N., Lebda, P., Kalman, P. G.
(2005). The Vascular Surgeon's Role in Risk Factor Modification: Results of a Survey. PERSPECT VASC SURG ENDOVASC THER
17: 145-153
[Abstract]
Woodard, L. D., Kressin, N. R., Petersen, L. A.
(2004). Is Lipid-Lowering Therapy Underused by African Americans at High Risk of Coronary Heart Disease Within the VA Health Care System?. AJPH
94: 2112-2117
[Abstract][Full Text]
Curb, J. D., Abbott, R. D., Rodriguez, B. L., Masaki, K. H., Chen, R., Popper, J. S., Petrovitch, H., Ross, G. W., Schatz, I. J., Belleau, G. C., Yano, K.
(2004). High Density Lipoprotein Cholesterol and the Risk of Stroke in Elderly Men: The Honolulu Heart Program. Am J Epidemiol
160: 150-157
[Abstract][Full Text]
Ho, P. M., Masoudi, F. A., Peterson, E. D., Grunwald, G. K., Sales, A. E., Hammermeister, K. E., Rumsfeld, J. S.
(2004). Cardiology management improves secondary prevention measures among patients with coronary artery disease. J Am Coll Cardiol
43: 1517-1523
[Abstract][Full Text]
Curb, J. D., Abbott, R. D., Rodriguez, B. L., Masaki, K., Chen, R., Sharp, D. S., Tall, A. R.
(2004). A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res.
45: 948-953
[Abstract][Full Text]
Viswambharan, H., Ming, X.-F., Zhu, S., Hubsch, A., Lerch, P., Vergeres, G., Rusconi, S., Yang, Z.
(2004). Reconstituted High-Density Lipoprotein Inhibits Thrombin-Induced Endothelial Tissue Factor Expression Through Inhibition of RhoA and Stimulation of Phosphatidylinositol 3-Kinase but not Akt/Endothelial Nitric Oxide Synthase. Circ. Res.
94: 918-925
[Abstract][Full Text]
Rye, K.-A., Barter, P. J.
(2004). Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I. Arterioscler. Thromb. Vasc. Bio.
24: 421-428
[Abstract][Full Text]
Fonarow, G. C., Horwich, T. B.
(2003). Cholesterol and mortality in heart failure: the bad gone good?. J Am Coll Cardiol
42: 1941-1943
[Full Text]
Gill, J. M., Brown, J. C, Caslake, M. J, Wright, D. M, Cooney, J., Bedford, D., Hughes, D. A, Stanley, J. C, Packard, C. J
(2003). Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. Am. J. Clin. Nutr.
78: 47-56
[Abstract][Full Text]
Friday, K. E.
(2003). Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials. Exp. Biol. Med.
228: 769-778
[Abstract][Full Text]
Pavo, I., Jermendy, G., Varkonyi, T. T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M., Herz, M., Johns, D., Schluchter, B. J., Festa, A., Tan, M. H.
(2003). Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab.
88: 1637-1645
[Abstract][Full Text]
Feher, M. D
(2003). Lipid lowering to delay the progression of coronary artery disease. Heart
89: 451-458
[Full Text]
McDermott, M. M., Guralnik, J. M., Greenland, P., Pearce, W. H., Criqui, M. H., Liu, K., Taylor, L., Chan, C., Sharma, L., Schneider, J. R., Ridker, P. M, Green, D., Quann, M.
(2003). Statin Use and Leg Functioning in Patients With and Without Lower-Extremity Peripheral Arterial Disease. Circulation
107: 757-761
[Abstract][Full Text]
Bermudez, O. I, Velez-Carrasco, W., Schaefer, E. J, Tucker, K. L
(2002). Dietary and plasma lipid, lipoprotein, and apolipoprotein profiles among elderly Hispanics and non-Hispanics and their association with diabetes. Am. J. Clin. Nutr.
76: 1214-1221
[Abstract][Full Text]
Pigeon, R. M., Cuesta, E. P., Gilliland, S. E.
(2002). Binding of Free Bile Acids by Cells of Yogurt Starter Culture Bacteria. J DAIRY SCI
85: 2705-2710
[Abstract][Full Text]
Longo, M, Crosignani, A, Battezzati, P M, Squarcia Giussani, C, Invernizzi, P, Zuin, M, Podda, M
(2002). Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut
51: 265-269
[Abstract][Full Text]
Yarzebski, J., Bujor, C. F., Goldberg, R. J., Spencer, F., Lessard, D., Gore, J. M.
(2002). A Community-Wide Survey of Physician Practices and Attitudes Toward Cholesterol Management in Patients With Recent Acute Myocardial Infarction. Arch Intern Med
162: 797-804
[Abstract][Full Text]
Kromhout, D., Menotti, A., Kesteloot, H., Sans, S.
(2002). Prevention of Coronary Heart Disease by Diet and Lifestyle: Evidence From Prospective Cross-Cultural, Cohort, and Intervention Studies. Circulation
105: 893-898
[Full Text]
Cobbe, S.M.
(2002). How best to combat the enemies? Lipid lowering. Eur Heart J Suppl
4: A48-A52
[Abstract]
Takemoto, M., Liao, J. K.
(2001). Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Arterioscler. Thromb. Vasc. Bio.
21: 1712-1719
[Abstract][Full Text]
Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., Bush, T. L.
(2001). Non-High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality. Arch Intern Med
161: 1413-1419
[Abstract][Full Text]
Kalmansohn, R. B., Kalmansohn, R. W., Schiff, D. L.
(2001). Scientific Communications: Revised Indications for Statin Therapies. ANGIOLOGY
52: 367-368
Gubitz, G., Sandercock, P.
(2000). Regular review: Prevention of ischaemic stroke. BMJ
321: 1455-1459
[Full Text]
Perez, A., Wagner, A. M., Carreras, G., Gimenez, G., Sanchez-Quesada, J. L., Rigla, M., Gomez-Gerique, J. A., Pou, J. M., de Leiva, A.
(2000). Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus: Effect of Glycemic Control. Arch Intern Med
160: 2756-2762
[Abstract][Full Text]
Koh, K. K.
(2000). Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res
47: 648-657
[Abstract][Full Text]
Ferro, D., Parrotto, S., Basili, S., Alessandri, C., Violi, F.
(2000). Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol
36: 427-431
[Abstract][Full Text]
Baigent, C., Wheeler, D. C.
(2000). Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?. Nephrol Dial Transplant
15: 1118-1119
[Full Text]
(2000). Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease : The Bezafibrate Infarction Prevention (BIP) Study. Circulation
102: 21-27
[Abstract][Full Text]
Haffner, S. M.
(2000). Is All Coronary Heart Disease Prevention in Type 2 Diabetes Mellitus Secondary Prevention?. J. Clin. Endocrinol. Metab.
85: 2108-2110
[Full Text]
Lindstrom, M., Hanson, B. S, Brunner, E., Wirfalt, E., Elmstahl, S., Mattisson, I., Ostergren, P.-O.
(2000). Socioeconomic differences in fat intake in a middle-aged population: report from the Malmo Diet and Cancer Study. Int J Epidemiol
29: 438-448
[Abstract][Full Text]
Akosah, K. O., Gower, E., Groon, L., Rooney, B. L., Schaper, A.
(2000). Mild hypercholesterolemia and premature heart disease: do the national criteria underestimate disease risk?. J Am Coll Cardiol
35: 1178-1184
[Abstract][Full Text]
Morocutti, G., Tuniz, D., Fioretti, P.M.
(1999). Comprehensive cardiac rehabilitation: an issue to be readdressed. Eur Heart J
20: 1448-1450
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J., Wittes, J., The Veterans Affairs High-Density Lipoprotein Chol,
(1999). Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. NEJM
341: 410-418
[Abstract][Full Text]
Pfeffer, M. A., Sacks, F. M., Moye, L. A., East, C., Goldman, S., Nash, D. T., Rouleau, J. R., Rouleau, J. L., Sussex, B. A., Theroux, P., Vanden Belt, R. J., Braunwald, E.
(1999). Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. J Am Coll Cardiol
33: 125-130
[Abstract][Full Text]
Cleeman, J. I., Lenfant, C.
(1998). The National Cholesterol Education Program: Progress and Prospects. JAMA
280: 2099-2104
[Abstract][Full Text]
Neunteufl, T., Kostner, K., Katzenschlager, R., Zehetgruber, M., Maurer, G., Weidinger, F.
(1998). Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol
32: 711-716
[Abstract][Full Text]
Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M.
(1998). Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. NEJM
339: 229-234
[Abstract][Full Text]
British Cardiac Society, , British Hyperlipidaemia Association, , British Hypertension Society, , endorsed by the British Diabetic Association,
(1998). Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart
80: 1S-29
[Full Text]
Rosenson, R. S., Tangney, C. C.
(1998). Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction. JAMA
279: 1643-1650
[Abstract][Full Text]
Sacks, F. M., Moye, L. A., Davis, B. R., Cole, T. G., Rouleau, J. L., Nash, D. T., Pfeffer, M. A., Braunwald, E.
(1998). Relationship Between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events Trial. Circulation
97: 1446-1452
[Abstract][Full Text]
Kato, H., Okada, R., Oogushi, K., Emura, S., Kishikawa, H., Kawazoye, S., Fukuoka, M., Takashima, T., Ohmori, K.
(1998). Suppressive Effect of Simvastatin on Intramural Small Coronary Arterial Lesions in Cholesterol-Fed Rabbits. ANGIOLOGY
49: 211-220
[Abstract]
Forrester, J. S., Shah, P. K.
(1997). Lipid Lowering Versus Revascularization : An Idea Whose Time (For Testing) Has Come*. Circulation
96: 1360-1362
[Abstract][Full Text]
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., Davis, B. R., Braunwald, E., The Cholesterol and, , Recurrent Events Trial Investigators,
(1996). The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. NEJM
335: 1001-1009
[Abstract][Full Text]
Frost, P. H., Davis, B. R., Burlando, A. J., David Curb, J., Guthrie, G. P. Jr, Isaacsohn, J. L., Wassertheil-Smoller, S., Wilson, A. C., Stamler, J.
(1996). Coronary Heart Disease Risk Factors in Men and Women Aged 60 Years and Older : Findings From the Systolic Hypertension in the Elderly Program. Circulation
94: 26-34
[Abstract][Full Text]
Rosenson, R. S.
(1996). Beyond Low-Density Lipoprotein Cholesterol: A Perspective on Low High-Density Lipoprotein Disorders and Lp(a) Lipoprotein Excess. Arch Intern Med
156: 1278-1284
[Abstract]
Paunio, M., Virtamo, J., Gref, C.-G., Heinonen, O. P
(1996). Serum high density lipoprotein cholesterol, alcohol, and coronary mortality in male smokers. BMJ
312: 1200-1203
[Abstract][Full Text]
Kuller, L.H., Shemanski, L., Psaty, B.M., Borhani, N.O., Gardin, J., Haan, M.N., O'Leary, D.H., Savage, P.J., Tell, G.S., Tracy, R.
(1995). Subclinical Disease as an Independent Risk Factor for Cardiovascular Disease. Circulation
92: 720-726
[Abstract][Full Text]
Havel, R. J., Rapaport, E.
(1995). Management of Primary Hyperlipidemia. NEJM
332: 1491-1498
[Full Text]
Stamos, T., Rosenson, R. S.
(1995). Cholesterol and Coronary Heart Disease Risk in Elderly Patients. JAMA
273: 1330-1330
[Abstract]
Levine, G. N., Keaney, J. F., Vita, J. A.
(1995). Cholesterol Reduction in Cardiovascular Disease -- Clinical Benefits and Possible Mechanisms. NEJM
332: 512-521
[Full Text]
Grundy, S. M.
(1994). Target Levels for Low-Density Lipoprotein in Patients With Coronary Heart Disease-Reply. JAMA
271: 101-102
[Abstract]
Rosenson, R. S.
(1993). Low Levels of High-Density Lipoprotein Cholesterol (Hypoalphalipoproteinemia) An Approach to Management. Arch Intern Med
153: 1528-1538
[Abstract]
Hulley, S. B., Newman, T. B., Grady, D., Garber, A. M., Baron, R. B., Browner, W. S.
(1993). Should We Be Measuring Blood Cholesterol Levels in Young Adults?. JAMA
269: 1416-1419
[Abstract]
Rubins, H. B., Schectman, G., Wilt, T. J., Iwane, M. K.
(1992). Distribution of Lipid Phenotypes in Community-Living Men With Coronary Heart Disease: High Prevalence of Isolated Low Levels of High-Density Lipoprotein Cholesterol. Arch Intern Med
152: 2412-2416
[Abstract]
Neaton, J. D., Blackburn, H., Jacobs, D., Kuller, L., Lee, D.-J., Sherwin, R., Shih, J., Stamler, J., Wentworth, D.
(1992). Serum Cholesterol Level and Mortality Findings for Men Screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med
152: 1490-1500
[Abstract]
Criqui, M. H.
(1991). Cholesterol, Primary and Secondary Prevention, and All-Cause Mortality. ANN INTERN MED
115: 973-976
[Abstract]
Wong, N. D., Wilson, P. W. F., Kannel, W. B.
(1991). Serum Cholesterol as a Prognostic Factor after Myocardial Infarction: The Framingham Study. ANN INTERN MED
115: 687-693
[Abstract]
Browner, W. S., Westenhouse, J., Tice, J. A.
(1991). What If Americans Ate Less Fat? A Quantitative Estimate of the Effect on Mortality. JAMA
265: 3285-3291
[Abstract]
(1990). CHOLESTEROL REMAINS A STRONG RISK FACTOR IN MEN WITH CARDIOVASCULAR DISEASE. JWatch General
1990: 1-1
[Full Text]
Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A.H., Hague, W., Keech, A., Thompson, P., White, H., Shaw, J., Tonkin, A.
(2002). Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels?. Circulation
105: 1162-1169
[Abstract][Full Text]
Previous
